TNFRSF17 and plasma cell myeloma: To observe the efficacy and safety of humanized anti-BCMA chimeric antigen receptor modified(BCMA CAR)-T cell therapy after disease progression with their murine BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (MM).